What BiomX Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 4 |
| Total trades | 0 | 8 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 8 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Yeganeh Reuven | Director | Mar 17 | Open-market sale · S | −530,000 | $5.00 | −$2.65M | 0 |
| Yeganeh Reuven | Director | Mar 17 | Derivative Conversion · C | +530,000 | $2.00 | +$1.06M | 530,000 |
| Yeganeh Reuven | Director | Mar 16 | Open-market sale · S | −450,000 | $5.00 | −$2.25M | 0 |
| Yeganeh Reuven | Director | Mar 16 | Derivative Conversion · C | +450,000 | $2.00 | +$900K | 450,000 |
| Yeganeh Reuven | Director | Mar 13 | Open-market sale · S | −370,000 | $5.00 | −$1.85M | 0 |
| Yeganeh Reuven | Director | Mar 13 | Derivative Conversion · C | +370,000 | $2.00 | +$740K | 370,000 |
| Yeganeh Reuven | Director | Mar 12 | Open-market sale · S | −300,000 | $5.00 | −$1.5M | 0 |
| Yeganeh Reuven | Director | Mar 11 | Derivative Conversion · C | +300,000 | $2.00 | +$600K | 30,000 |
| Wolfson Marina | Chief Financial Officer | Apr 14 | Grant / award · A | +68,545 | — | — | 68,545 |
| Solomon Jonathan Eitan | Chief Executive Officer | Apr 14 | Grant / award · A | +126,748 | — | — | 126,748 |
| Bassan Merav | Chief Development Officer | Apr 14 | Grant / award · A | +79,597 | — | — | 79,597 |
| Flynn James E | Director | Feb 27 | Exercise / conversion · M | +353,249 | $0.93 | +$329K | 1,247,054 |
| Flynn James E | Director | Feb 27 | Exercise / conversion · M | +353,249 | $0.93 | +$329K | 1,247,054 |
| Oron Assaf | Chief Business Officer | Sep 16 | Grant / award · A | +25,804 | — | — | 25,804 |
| Solomon Jonathan Eitan | Chief Executive Officer | Sep 16 | Grant / award · A | +50,556 | — | — | 53,056 |
| Bassan Merav | Chief Development Officer | Sep 16 | Grant / award · A | +31,749 | — | — | 31,749 |
| Flynn James E | Director | Jul 15 | Exercise / conversion · M | +5,883,000 | — | — | 8,938,049 |
| Flynn James E | Director | Jul 15 | Exercise / conversion · M | +5,883,000 | — | — | 8,938,049 |
| Cystic Fibrosis Foundation | 10% owner | Jul 15 | Derivative Conversion · C | +854,700 | — | — | 1,787,758 |
| Cystic Fibrosis Foundation | 10% owner | May 15 | In/At-money Exercise · X | +4,778,265 | $0.00 | +$4.78K | 9,330,580 |
Loading...
